Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares Global Clean Energy ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while iShares Global Clean Energy ETF trades at $18.43. The key difference: iShares Global Clean Energy ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ICLN | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | — |
52-Week High | $491.22 | $23.75 |
52-Week Low | $205.48 | $13.66 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
ICLN, the iShares Global Clean Energy ETF, trades at $18.41, up 1.83% today, but technical indicators signal a bearish trend with moving averages and overall momentum pointing lower. The fund provides exposure to 105 global renewable energy companies, though key valuation and profitability ratios are not publicly disclosed for the ETF itself. Recent news highlights strong 2026 performance with over 25% gains, driven by global energy security concerns and data center power demand, though it faces competition from traditional energy ETFs offering lower fees and higher yields.
The outlook for ICLN is mixed; clean energy tailwinds from policy support and electrification trends offer growth potential, but risks include regulatory hurdles, fee competitiveness, and volatility. Analyst sentiment is cautious due to fee comparisons and policy dependence, with institutional interest balanced against outperformance of alternatives like uranium ETFs. Investment suitability hinges on appetite for clean energy sector volatility versus stable income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
